International initiative TESLA identifies parameters for cancer vaccine or cell therapy advancement

Published in Cell: TRON is part of a 36-member alliance led by the Parker Institute and Cancer Research Institute identifying parameters for better vaccine design in the fight against cancer.

As part of TESLA (Tumor Neoantigen Selection Alliance), TRON performed advanced computational analysis on samples from melanoma and non-small cell lung cancer to identify characteristics that strongly indicate which cancer markers are most likely to generate an immune response. These findings could improve drug makers’ and researchers’ algorithms, prioritizing “effective” antigens and ultimately mean better individualized treatments for patients.

Find out more from the official press release here and read the Cell article here.